6.
Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P
. Factors affecting outcomes in Crohn's disease over 15 years. Gut. 2012; 61(8):1140-5.
PMC: 3388724.
DOI: 10.1136/gutjnl-2011-301971.
View
7.
Ungaro R, Yzet C, Bossuyt P, Baert F, Vanasek T, DHaens G
. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology. 2020; 159(1):139-147.
PMC: 7751802.
DOI: 10.1053/j.gastro.2020.03.039.
View
8.
Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E
. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol. 2016; 51(6):712-9.
DOI: 10.3109/00365521.2015.1128965.
View
9.
Khanna R, Nelson S, Feagan B, DHaens G, Sandborn W, Zou G
. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016; (8):CD010642.
PMC: 7079710.
DOI: 10.1002/14651858.CD010642.pub2.
View
10.
Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S
. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A:5A-36A.
DOI: 10.1155/2005/269076.
View
11.
Schaffer T, Schoepfer A, Seibold F
. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. J Crohns Colitis. 2014; 8(9):1125-32.
DOI: 10.1016/j.crohns.2014.02.014.
View
12.
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert J, Raine T
. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2019; 14(1):4-22.
DOI: 10.1093/ecco-jcc/jjz180.
View
13.
Claytor J, Kumar P, Ananthakrishnan A, Colombel J, Agrawal M, Ungaro R
. Mild Crohn's Disease: Definition and Management. Curr Gastroenterol Rep. 2023; 25(3):45-51.
DOI: 10.1007/s11894-023-00863-y.
View
14.
Narula N, Wong E, Dulai P, Patel J, Marshall J, Yzet C
. Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression. Clin Gastroenterol Hepatol. 2024; 22(8):1687-1696.e6.
DOI: 10.1016/j.cgh.2024.02.009.
View
15.
Lewis J, Parlett L, Jonsson Funk M, Brensinger C, Pate V, Wu Q
. Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology. 2023; 165(5):1197-1205.e2.
PMC: 10592313.
DOI: 10.1053/j.gastro.2023.07.003.
View
16.
Schoepfer A, Beglinger C, Straumann A, Trummler M, Vavricka S, Bruegger L
. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2009; 105(1):162-9.
DOI: 10.1038/ajg.2009.545.
View
17.
Swaminathan A, Borichevsky G, Frampton C, Kettle A, Peyrin-Biroulet L, Siegel C
. Development and investigation of a non-invasive disease severity index for inflammatory bowel disease. J Crohns Colitis. 2024; .
PMC: 11637517.
DOI: 10.1093/ecco-jcc/jjae106.
View
18.
Siegel C, Whitman C, Spiegel B, Feagan B, Sands B, Loftus Jr E
. Development of an index to define overall disease severity in IBD. Gut. 2016; 67(2):244-254.
DOI: 10.1136/gutjnl-2016-312648.
View
19.
Sipponen T, Karkkainen P, Savilahti E, Kolho K, Nuutinen H, Turunen U
. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008; 28(10):1221-9.
DOI: 10.1111/j.1365-2036.2008.03835.x.
View
20.
Feuerstein J, Ho E, Shmidt E, Singh H, Falck-Ytter Y, Sultan S
. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology. 2021; 160(7):2496-2508.
PMC: 8988893.
DOI: 10.1053/j.gastro.2021.04.022.
View